Mechanisms of Very Late DES Thrombosis by OCT

Original Title: Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. Reference: Masanori Taniwaki et al. Circulation. 2016 Feb 16;133(7):650-60.

 

The physiopathological mechanisms behind DES thrombosis have not been fully described yet. The potential causes behind this adverse event were assessed using optical computed tomography (OCT).

Between August 2010 and December 2014, 64 patients with instent very late thrombosis were included as part of an international OCT registry.
Very late thrombosis occurred at median 4.7 years after the original procedure (range 3.1 to 7.5 years).

After restoration of flow, OCT pullbacks were performed to analyze 38 first generation DES and 20 new generation DES; a possible cause was observed 98% of times.

The most frequent findings were strut malapposition (34.5%), neo atherosclerosis (27.6%), uncovered struts (12.1%) and stent underexpansion (6.9%).

Uncovered struts and malapposition were more frequent in thrombosed regions vs. non thrombosed.

Maximum stent length with absence or malapposed intimal covering (3.40 mm vs 1.29 mm; p<0.001) was a very strong predictor of thrombosis, but not malapposition distance (distance separating struts from intimal covering).

The combination of malapposition and absence of covering was consistent in both DES generations.

Conclusion
The most frequent causes of very late thrombosis were malapposition, neoatherosclerosis, uncovered struts and underexpansion, across first and new generation DES.

The maximal length of malapposed or uncovered struts showed the highest correlation with very late thrombosis.

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...